1
|
McGree JM, Hockham C, Kotwal S, Wilcox A, Bassi A, Pollock C, Burrell LM, Snelling T, Jha V, Jardine M, Jones M. Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial. Trials 2022; 23:361. [PMID: 35477480 PMCID: PMC9044378 DOI: 10.1186/s13063-022-06167-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2021] [Accepted: 03/10/2022] [Indexed: 11/10/2022] Open
Abstract
The CLARITY trial (Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease) is a two-arm, multi-centre, randomised controlled trial being run in India and Australia that investigates the effectiveness of angiotensin receptor blockers in addition to standard care compared to placebo (in Indian sites) with standard care in reducing the duration and severity of lung failure in patients with COVID-19. The trial was designed as a Bayesian adaptive sample size trial with regular planned analyses where pre-specified decision rules will be assessed to determine whether the trial should be stopped due to sufficient evidence of treatment effectiveness or futility. Here, we describe the statistical analysis plan for the trial and define the pre-specified decision rules, including those that could lead to the trial being halted. The primary outcome is clinical status on a 7-point ordinal scale adapted from the WHO Clinical Progression scale assessed at day 14. The primary analysis will follow the intention-to-treat principle. A Bayesian adaptive trial design was selected because there is considerable uncertainty about the extent of potential benefit of this treatment. Trial registration ClinicalTrials.gov NCT04394117. Registered on 19 May 2020Clinical Trial Registry of India CTRI/2020/07/026831 Version and revisions Version 1.0. No revisions.
Collapse
Affiliation(s)
- J M McGree
- School of Mathematical Sciences, Queensland University of Technology, Brisbane, Australia.
| | - C Hockham
- The George Institute for Global Health, University of New South Wales, Sydney, Australia.,The George Institute for Global Health, Imperial College London, London, UK
| | - S Kotwal
- The George Institute for Global Health, University of New South Wales, Sydney, Australia.,Prince of Wales Hospital, Sydney, Australia
| | - A Wilcox
- The George Institute for Global Health, University of New South Wales, Sydney, Australia.,NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia
| | - A Bassi
- The George Institute for Global Health, New Delhi, India
| | - C Pollock
- Royal North Shore Hospital, Sydney, Australia.,Kolling Institute of Medical Research, The University of Sydney, Sydney, Australia
| | - L M Burrell
- Department of Medicine, The University of Melbourne, Austin Health, Heidelberg, Victoria, Australia
| | - T Snelling
- Sydney School of Public Health, The University of Sydney, Sydney, Australia.,The Sydney Children's Hospitals Network, Westmead, Australia
| | - V Jha
- The George Institute for Global Health, University of New South Wales, Sydney, Australia.,The George Institute for Global Health, New Delhi, India
| | - M Jardine
- The George Institute for Global Health, University of New South Wales, Sydney, Australia.,NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia.,Concord Repatriation General Hospital, Sydney, Australia
| | - M Jones
- Sydney School of Public Health, The University of Sydney, Sydney, Australia
| | | |
Collapse
|
2
|
Feng Y, Li Q, Finfer S, Myburgh J, Bellomo R, Perkovic V, Jardine M, Wang A, Gallagher M, Hong D. POS-019 A NOVEL RISK PREDICTION MODEL FOR SERVE ACUTE KIDNEY INJURY IN INTENSIVE CARE UNIT PATIENTS RECEIVING FLUID RESUSCITATION. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
3
|
Lambers Heerspink H, Jardine M, Kohan D, Lafayette R, Levin A, Liew A, Zhang H, Glicklich A, Camargo M, King A, Barratt J. POS-527 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study). Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
4
|
Neuen BL, Oshima M, Perkovic V, Arnott C, Bakris G, Cannon CP, Charytan DM, Jardine M, Levin A, Neal B, Pollock C, Wheeler DC, Mahaffey KW, Heerspink HJL. Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2647] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Hyperkalaemia is a common complication of type 2 diabetes mellitus (T2DM) and limits the optimal use of agents that block the renin-angiotensin aldosterone system (RAAS), particularly in patients with chronic kidney disease (CKD). In patients with CKD, sodium glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection, but whether they affect the risk of hyperkalaemia remains uncertain.
Purpose
We sought to assess the effect of canagliflozin on hyperkalaemia and other potassium-related outcomes in people with T2DM and CKD by conducting a post-hoc analysis of the CREDENCE trial.
Methods
The CREDENCE trial randomized 4401 participants with T2DM and CKD to the SGLT2 inhibitor canagliflozin or matching placebo. In this post-hoc analysis using an intention-to-treat approach, we assessed the effect of canagliflozin on a composite outcome of time to either investigator-reported hyperkalaemia or the initiation of potassium binders. We also analysed effects on central laboratory-determined hyper- and hypokalaemia (serum potassium ≥6.0 and <3.5 mmol/L, respectively) and change in serum potassium.
Results
At baseline the mean serum potassium in canagliflozin and placebo arms was 4.5 mmol/L; 4395 (99.9%) participants were receiving renin angiotensin system blockade. Canagliflozin reduced the risk of investigator-reported hyperkalaemia or initiation of potassium binders (HR 0.78, 95% CI 0.64–0.95, p=0.014; Figure 1). The incidence of laboratory-determined hyperkalaemia was similarly reduced (HR 0.77, 95% CI 0.61–0.98, p=0.031; Figure 2); the risk of hypokalaemia (HR 0.92, 95% CI 0.71–1.20, p=0.53) was not increased. Mean serum potassium over time with canagliflozin was similar to that of placebo.
Conclusion
Among patients treated with RAAS inhibitors, SGLT2 inhibition with canagliflozin may reduce the risk of hyperkalaemia in people with T2DM and CKD without increasing the risk of hypokalaemia.
Funding Acknowledgement
Type of funding sources: None. Figure 1Figure 2
Collapse
Affiliation(s)
- B L Neuen
- The George Institute for Global Health, Sydney, Australia
| | - M Oshima
- The George Institute for Global Health, Sydney, Australia
| | - V Perkovic
- University of New South Wales Sydney, Sydney, Australia
| | - C Arnott
- The George Institute for Global Health, Sydney, Australia
| | - G Bakris
- University of Chicago Medicine, Chicago, United States of America
| | - C P Cannon
- Harvard Medical School, Boston, United States of America
| | - D M Charytan
- New York University Langone Medical Center, New York, United States of America
| | - M Jardine
- University of Sydney, Sydney, Australia
| | - A Levin
- University of British Columbia, Vancouver, Canada
| | - B Neal
- The George Institute for Global Health, Sydney, Australia
| | - C Pollock
- University of Sydney, Sydney, Australia
| | - D C Wheeler
- University College London, London, United Kingdom
| | - K W Mahaffey
- Stanford University Medical Center, Stanford, United States of America
| | - H J L Heerspink
- University Medical Center Groningen, Groningen, Netherlands (The)
| |
Collapse
|
5
|
Mahaffey K, Li J, Chang T, Sarraju A, Agarwal R, Charytan D, Greene T, Heerspink H, Levin A, Neal B, Pollock C, Yavin Y, Jardine M, Perkovic V, Cannon C. Independent predictors of heart failure in patients with type 2 diabetes and chronic kidney disease: modeling from the CREDENCE trial. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
SGLT2 inhibitors have been shown to reduce hospitalization for heart failure (HHF). We sought to determine independent baseline predictors for HHF specifically in a population with type 2 diabetes and chronic kidney disease (CKD).
Methods
CREDENCE randomized 4401 participants with type 2 diabetes and CKD to canagliflozin 100 mg versus placebo. We evaluated the baseline clinical and demographic factors using multivariate regression modeling to identify the independent predictors of HHF.
Results
Overall, 230 participants (89 canagliflozin; 141 placebo) had at least 1 HHF event. Canagliflozin reduced the incidence of HHF compared with placebo (4.0% vs 6.4%; HR 0.61; 95% CI 0.47–0.80). Participants with HHF events postrandomization were older (65.8 vs 62.9 y), and had a longer duration of diabetes (17.4 vs 15.7 y), higher prevalence of prior HF (30.4% vs 14.0%), higher urinary albumin:creatinine ratio (1347 vs 904 mg/g), lower estimated glomerular filtration rate (51.5 vs 56.4 mL/min/1.73m2), and higher prevalence of prior cardiovascular disease (65.7% vs 49.6%) compared to those without HHF. Independent predictors of HHF are shown in the Table.
Conclusions
HHF is common in patients with type 2 diabetes and CKD. Canagliflozin reduces HHF by 39% compared with placebo. Higher urinary albumin:creatinine ratio was the most potent predictor of HHF and should be part of patient risk assessment.
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Janssen Research & Development, LLC
Collapse
Affiliation(s)
- K.W Mahaffey
- Stanford Center for Clinical Research, Dept of Medicine, Stanford University School of Medicine, Stanford, CA, United States of America
| | - J Li
- The George Institute for Global Health, UNSW Sydney, Sydney, Australia
| | - T.I Chang
- Stanford Center for Clinical Research, Dept of Medicine, Stanford University School of Medicine, Stanford, CA, United States of America
| | - A Sarraju
- Stanford Center for Clinical Research, Dept of Medicine, Stanford University School of Medicine, Stanford, CA, United States of America
| | - R Agarwal
- Indiana University School of Medicine and VA Medical Center, Indianapolis, IN, United States of America
| | - D.M Charytan
- Nephrology Division, NYU School of Medicine and NYU Langone Medical Center, New York, NY, United States of America
| | - T Greene
- Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City, UT, United States of America
| | - H.J.L Heerspink
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands (The)
| | - A Levin
- Division of Nephrology, University of British Columbia, Vancouver, BC, Canada
| | - B Neal
- The George Institute for Global Health, UNSW Sydney, Sydney, Australia
| | - C Pollock
- Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital, St Leonards, NSW, Australia
| | - Y Yavin
- Janssen Research & Development, LLC, Raritan, NJ, United States of America
| | - M Jardine
- The George Institute for Global Health, UNSW Sydney, Sydney, Australia
| | - V Perkovic
- The George Institute for Global Health, UNSW Sydney, Sydney, Australia
| | - C.P Cannon
- Cardiovasular Division, Brigham & Women's Hospital and Baim Institute for Clinical Research, Boston, MA, United States of America
| |
Collapse
|
6
|
OSHIMA M, Wong M, Hara A, Toyama T, Jun M, Jardine M, Pollock C, Woodward M, Chalmers J, Perkovic V, Wada T. SUN-161 CIRCULATING AUTOANTIBODIES TO ERYTHROPOIETIN RECEPTOR AND KIDNEY DISEASE PROGRESSION IN TYPE 2 DIABETES MELLITUS: RESULTS FROM THE ADVANCE STUDIES. Kidney Int Rep 2020. [DOI: 10.1016/j.ekir.2020.02.690] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
7
|
Starblanket D, O’Connell M, Gould B, Jardine M, Ferguson M, Bourassa C. Defining technology user needs of Indigenous older adults requiring dementia care. ACTA ACUST UNITED AC 2019. [DOI: 10.4017/gt.2019.18.3.002.00] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
8
|
Toyama T, NEUEN B, Jun M, Ohkuma T, Neal B, Jardine M, Heerspink H, Ninomiya T, Wada T, Perkovic V. SAT-298 EFFECT OF SGLT2 INHIBITORS ON CARDIOVASCULAR, RENAL AND SAFETY OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
9
|
YOUNG T, Hockham C, Sukkar L, Kang A, Jun M, Baker J, Rogers K, Cass A, Jardine M. SAT-288 Trends in pharmacotherapy for diabetes in a large Australian cohort: results from the EXTEND45 study. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
10
|
HOCKHAM C, Kang A, Young T, Sukkar L, Jun M, Rogers K, Baker J, Cass A, Jardine M. SAT-241 SMALL AREA-LEVEL VARIATION IN CHRONIC KIDNEY DISEASE PREVALENCE AND INCIDENCE IN NEW SOUTH WALES. Kidney Int Rep 2019. [DOI: 10.1016/j.ekir.2019.05.277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
11
|
Woodward M, Hirakawa Y, Kengne AP, Matthews DR, Zoungas S, Patel A, Poulter N, Grobbee R, Cooper M, Jardine M, Chalmers J. Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score. Diabetes Obes Metab 2016; 18:289-94. [PMID: 26661693 DOI: 10.1111/dom.12614] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/03/2015] [Revised: 11/11/2015] [Accepted: 11/30/2015] [Indexed: 11/30/2022]
Abstract
AIMS To formulate a combined cardiovascular risk score in diabetes that could be useful both to physicians and healthcare funders. METHODS Data were derived from the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation Observational (ADVANCE-ON) study, a randomized controlled trial (mean duration 5 years) with a post-randomization follow-up (mean 4.9 years), that included 11 140 high-risk patients with diabetes. The outcome analysed was the occurrence of either fatal or non-fatal macrovascular or renal disease. A Cox regression model was used to determine weightings in the risk score. The resultant score was recalibrated to each of three major global regions, as covered by the ADVANCE-ON study. RESULTS Over a median of 9.9 years, 1145 patients experienced at least one component of the combined outcome event. The resultant score, the AD-ON risk score, incorporated 13 demographic or clinical variables. Its discrimination was modest [c-statistic = 0.668 (95% confidence interval 0.651, 0.685)] but its calibration was excellent (predicted and observed risks coincided well, within disparate global regions). In terms of the integrated discrimination improvement index, its performance was marginally superior, over a 10-year risk horizon, to existing risk scores in clinical use, from a restricted version of the same data, for macrovascular and renal disease separately. CONCLUSIONS The AD-ON risk score has advantages over the existing vascular risk scores in diabetes that used data from the original ADVANCE trial, which treat macrovascular and renal diseases separately. These advantages include its simplicity of use and global application.
Collapse
Affiliation(s)
- M Woodward
- George Institute for Global Health, University of Sydney, Sydney, Australia
- George Institute for Global Health, Nuffield Department of Population Health, University of Oxford, Oxford, UK
- Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA
| | - Y Hirakawa
- George Institute for Global Health, University of Sydney, Sydney, Australia
| | - A-P Kengne
- George Institute for Global Health, University of Sydney, Sydney, Australia
- Non-Communicable Diseases Research Unit, South African Medical Research Council, University of Cape Town, Cape Town, South Africa
| | - D R Matthews
- Oxford Centre for Diabetes, Endocrinology Metabolism, University of Oxford, Oxford, UK
| | - S Zoungas
- George Institute for Global Health, University of Sydney, Sydney, Australia
- Monash Centre for Health Research and Implementation, School of Public Health and Preventive Medicine, Monash University, Clayton, Australia
| | - A Patel
- George Institute for Global Health, University of Sydney, Sydney, Australia
| | - N Poulter
- International Centre for Circulatory Health, Imperial College London, London, UK
| | - R Grobbee
- Julius Global Health, the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
| | - M Cooper
- The Baker IDI Heart and Diabetes Institute, Melbourne, Australia
| | - M Jardine
- George Institute for Global Health, University of Sydney, Sydney, Australia
| | - J Chalmers
- George Institute for Global Health, University of Sydney, Sydney, Australia
| |
Collapse
|
12
|
Neves FMDO, Leite TT, Meneses GC, Araujo De Souza NH, Martins AMC, Parahyba MC, Queiroz REB, Liborio A, Liu Y, Li Y, Li X, Chen L, Zulkarnaev A, Vatazin A, Nikolaj S, Stadler T, Raddatz A, Hubner W, Poppleton A, Fliser D, Klingele M, Castellano G, Intini A, Stasi A, Divella C, Pontrelli P, Gigante M, Zito A, Pertosa GB, Gesualdo L, Grandaliano G, Powell TC, Donnelly JP, Wang HE, Warnock DG, De Loor J, Hoste E, Herck I, Francois K, Decrop L, Clauwaert C, Bracke S, Vermeiren D, Demeyere K, Meyer E, Mitra P, Rahim MA, Gupta RD, Samdani TS, Rahman SA, Enam SF, Mursalin G, E-Khoda MM, Haque WMM, Iqbal S, Mansur MA, Guglielmetti G, Cena T, Musetti C, Quaglia M, Battista M, Radin E, Airoldi A, Izzo C, Stratta P, Haase-Fielitz A, Albert C, Westphal S, Hoffmann J, Mertens PR, Plass M, Westerman M, Bellomo R, Maisel A, Ronco C, Haase M, Wu PC, Wu VC, Prasad B, Wong B, St.Onge JR, Rungta R, Das P, Ray DS, Gupta S, De Gracia MDC, Osuna A, Quesada A, Manzano F, Montoro S, Jimenez MDM, Wangensteen R, Strunk AK, Schmidt J, Schmidt B, Bode-Boger S, Martens-Lobenhoffer J, Welte T, Kielstein JT, Wang AY, Bellomo R, Cass A, Myburgh J, Finfer S, Gatta D, Chadban S, Jardine M, Lo S, Barzi F, Gallagher M, Marn-Pernat A, Benedik M, Bren A, Buturovic-Ponikvar J, Gubensek J, Knap B, Premru V, Ponikvar R, Koba L, Teixeira M, Macedo E, Altunoren O, Balli M, Tasolar H, Eren N, Arpaci A, Caglayan CE, Yavuz YC, Sahin M, Gliga ML, Gliga PM, Frigy A, Bandea A, Magdas AM, Dogaru G, Mergulhao C, Pinheiro H, Vidal E, Sette L, Amorim G, Fernandes G, Valente L, Hornum M, Penninga L, Rasmussen A, Plagborg UB, Oturai P, Feldt-Rasmussen B, Hillingso JG, Klimenko A, Villevalde S, Kobalava Z, Arias Cabrales C, Rodriguez E, Bermejo S, Sierra A, Pascual J, Huang TM, Wu VC, Oh WC, Rigby M, Mafrici B, Sharman A, Harvey D, Welham S, Mahajan R, Gardner D, Devonald M, Wu VC, Lin MC, Wu PC, Wu CH, Nagaraja P, Clark A, Brisk R, Jennings V, Jones H, Hashmi M, Parker C, Mikhail A, Schraut J, Keller F, Mertens T, Duprel JB, Quercia AD, Cantaluppi V, Dellepiane S, Pacitti A, Biancone L, Chang KY, Park HS, Kim HW, Choi BS, Park CW, Yang CW, Jin DC, Quercia AD, Cantaluppi V, Dellepiane S, Medica D, Besso L, Gai M, Leonardi G, Guarena C, Biancone L, Obrencevic K, Jovanovic D, Petrovic M, Ignjatovic L, Tadic J, Mijuskovic M, Maksic D, Vavic N, Pilcevic D, Mistry HD, Bramham K, Seed PT, Lynham S, Ward MA, Poston L, Chappell LC. CLINICAL ACUTE KIDNEY INJURY 1. Nephrol Dial Transplant 2014. [DOI: 10.1093/ndt/gfu144] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Lau J, Chang M, Ordys B, Jardine M, Al-kahwa A, Sindone A. Chronic Kidney Disease is a Marker of Increased Risk and Co-morbidity in Heart Failure. Heart Lung Circ 2013. [DOI: 10.1016/j.hlc.2013.05.171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
14
|
Foote C, Ninomiya T, Gallagher M, Perkovic V, Cass A, McDonald SP, Jardine M. Survival of elderly dialysis patients is predicted by both patient and practice characteristics. Nephrol Dial Transplant 2012; 27:3581-7. [DOI: 10.1093/ndt/gfs096] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
15
|
Coentrao L, Ribeiro C, Santos-Araujo C, Neto R, Pestana M, Rahman E, Rahman H, Ahmed D, Mousa D, El Bishlawi M, Shibahara H, Shibahara N, Takahashi S, Dupuis E, Duval X, Dornic Q, Bonnal C, Lucet JC, Cerceau O, Randoux C, Balde C, Besson F, Mentre F, Vrtovsnik F, Koutroubas G, Malindretos P, Zagotsis G, Makri P, Syrganis C, Mambelli E, Mancini E, Elia C, Guadagno V, Facchini MG, Zucchelli A, Grazia M, Patregnani L, Santoro A, Stefan G, Stefan G, Stancu S, Capusa C, Ailioaiei OR, Mircescu G, Anwar S, Little C, Kingston R, Diwakar P, Kaikini R, Syrganis C, Koutroubas G, Zagotsis G, Malindretos P, Makri P, Nikolaou E, Loukas G, Sabry A, Alsaran K, Al Sherbeiny S, Abdulkader M, Kwak I, Song S, Seong E, Lee S, Lee D, Kim I, Rhee H, Silva F, Queiros J, Malheiro J, Cabrita A, Rocha A, Bamidis P, Bamidis P, Liaskos C, Chryssogonidis I, Frantzidis C, Papagiannis A, Vrochides D, Lasaridis A, Nikolaidis P, Malindretos P, Kotwal S, Muir C, Hawley C, Snelling P, Gallagher M, Jardine M, Shibata K, Shibata K, Toya Y, Umemura S, Iwamoto T, Ono S, Ikeda E, Kitazawa A, Kuji T, Koguchi N, Satta H, Nishihara M, Kawata S, Kaneda T, Yamada Y, Murakami T, Yanagi M, Yasuda G, Mathieu S, Yves D, Jean-Michel T, Nicolas Q, Jean-Francois C, Ibrahim M, Abdel Salam M, Awadalla A, Bichari W, Zaki S, Roca-Tey R, Samon R, Ibrik O, Roda A, Gonzalez-Oliva JC, Martinez-Cercos R, Viladoms J, Lin CC, Yang WC, Kim YO, Yoon SA, Yun YS, Song HC, Kim BS, Cheong MA, Ogawa T, Kiba T, Okazaki S, Hatano M, Iwanaga M, Noiri C, Matsuda A, Hasegawa H, Mitarai T, DI Napoli A, DI Lallo D, Tazza L, De Cicco C, Salvatori MF, Chicca S, Guasticchi G, Gelev S, Trajceska L, Srbinovska E, Pavleska S, Oncevski A, Dejanov P, Gerasomovska V, Selim G, Sikole A, Wilson S, Mayne T, Krishnan M, Holland J, Volz A, Good L, Nissenson A, Stavroulopoulos A, Aresti V, Maragkakis G, Kyriakides S, Rikker C, Rikker C, Juhasz E, Tornoci L, Tovarosi S, Greguschik J, Mag O, Rosivall L, Golebiowski T, Golebiowski T, Watorek E, Kusztal M, Letachowicz K, Letachowicz W, Madziarska K, Augustyniak Bartosik H, Krajewska M, Weyde W, Klinger M, Capitanini A, Lange S, Cupisti A, Schier T, Gobel G, Bosmuller C, Gruber I, Tiefenthaler M, Shipley T, Adam J, Sweeney D, Fenwick S, Mansy H, Ahmed S, Moore I, Iwamoto T, Shibata K, Yasuda G, Kaneda T, Murakami T, Kuji T, Koguchi N, Satta H, Nishihara M, Kawata S, Yanagi M, Yamada Y, Ono S, Ikeda E, Kitazawa A, Toya Y, Umemura S, Vigeral P, Saksi S, Flamant M, Boulanger H, Kim YO, Yoon SA, Yun YS, Song HC, Kim BS, Park WD, Cheong MA, Nikam M, Tavakoli A, Chemla E, Evans J, Malete H, Matyas L, Mogan I, Lazarides M, Ebner A, Shi Y, Shi Y, Zhang J, Cheng J, Frank LR, Melanie H, Dominique B, Michel G, Ikeda K, Yasuda T, Yotueda H, Nikam M, Ebah L, Jayanti A, Evans J, Kanigicherla D, Summers A, Manley G, Dutton G, Chalmers N, Mitra S, Checherita IA, Niculae A, Radulescu D, David C, Turcu FL, Ciocalteu A, Persic V, Persic V, Buturovic-Ponikvar J, Ponikvar R, Touam M, Touam M, Menoyo V, Drueke T, Rifaat M, Muresan C, Abtahi M, Koochakipour Z, Joly D, Baharani J, Rizvi S, Ng KP, Buzzi L, Sarcina C, Alberghini E, Ferrario F, Baragetti I, Santagostino G, Furiani S, Corghi E, Sarcina C, Terraneo V, Rastelli F, Bacchini G, Pozzi C, Adorati Menegato M, Mortellaro R, Locicero A, Romano A, Manzini PP, Steckiph D, Shintaku S, Kawanishi H, Moriishi M, Bansyodani M, Nakamura S, Saito M, Tsuchiya S, Barros F, Vaz R, Carvalho B, Neto R, Martins P, Pestana M, Likaj E, Likaj E, Seferi S, Rroji M, Idrizi A, Duraku A, Barbullushi M, Thereska N, Shintaku S, Kawanishi H, Moriishi M, Bansyodani M, Nakamura S, Saito M, Tsuchiya S. Vascular access. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs226] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Llama J, Wood K, Jardine M, Vidotto AA, Helling C, Fossati L, Haswell CA. The shocking transit of WASP-12b: modelling the observed early ingress in the near-ultraviolet. ACTA ACUST UNITED AC 2011. [DOI: 10.1111/j.1745-3933.2011.01093.x] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Tchebotareva N, Bobkova I, Kozlovskaya L, Li O, Plaisier E, Terrier B, Lacraz A, Bridoux F, Huart A, Marie I, Launay D, Hummel A, Saint-Martin L, Bonnet F, Belenotti P, Kahn JE, Hinschberger O, Rullier P, Cacoub P, Casian A, Szpirt W, Jayne D, Walsh M, Haris A, Polner K, Aranyi J, Braunitzer H, Meran Z, Kaszas I, Mazanowska O, Koscielska-Kasprzak K, Kaminska D, Penar J, Zabinska M, Dziemianko I, Krajewska M, Klinger M, Marco H, Corica M, Picazo M, Arce Y, Llobet JM, Diaz M, Ballarin J, Kuroki A, Akizawa T, Papasotiriou M, Kalliakmani P, Huang L, Gerolymos M, Goumenos DS, Johnson TS, Ogahara S, Abe Y, Ito K, Watanabe M, Saito T, Saito T, Watanabe M, Ito K, Abe Y, Ogahara S, Nesen A, Topchii I, Semenovylh P, Galchinskaya V, Bantis C, Heering P, Kouri NM, Schwandt C, Rump LC, Ivens K, Nagasawa Y, Iio K, Fukuda S, Date Y, Iwatani H, Yamamoto R, Horii A, Inohara H, Imai E, Ohno H, Rakugi H, Rakugi Y, Sahin OZ, Gibyeli Genek D, Alkan Tasli F, Yavas H, Gurses S, Yeniay P, Uzum A, Ersoy R, Cirit M, Christou D, Molyneux K, Peracha J, Feehally J, Smith AC, Barratt J, Yamamoto R, Nagasawa Y, Shoji T, Katakami N, Ohtoshi K, Hayaishi-Okano R, Yamasaki Y, Yamauchi A, Tsubakihara Y, Imai E, Rakugi H, Isaka Y, Faria B, Vidinha J, Pego C, Garrido J, Lemos S, Lima C, Sorbo G, Lorga E, Sousa T, Yavas HH, Sahin OZ, Ozen KP, Gibyeli Genek D, Ersoy R, Alkan Tasli F, Yucel O, Cirit M, Wada Y, Ogata H, Yamamoto M, Ito H, Kinugasa E, Lundberg S, Lundahl J, Gunnarsson I, Jacobson S, Camilla R, Loiacono E, Dapra V, Morando L, Conrieri M, Bianciotto M, Bosetti FM, Gallo R, Peruzzi L, Amore A, Coppo R, Jeong K, Kim Y, Lee TW, Lee SH, Moon JY, Lee S, Ihm C, Komatsu H, Fujimoto S, Kikuchi M, Sato Y, Kitamura K, Sulikowska B, Johnson R, Grajewska M, Donderski R, Odrowaz-Sypniewska G, Manitius J, Amore A, Camilla R, Morando L, Peruzzi L, Rollino C, Quarello F, Colla L, Segoloni G, Caramello E, Cravero R, Quaglia M, Stratta P, Mazzucco G, Coppo R, Coppo R, Grcevska L, Petrusevska G, Nikolov V, Polenakovic M, Lee KW, Ham YR, Jang WI, Jung JY, Jang DS, Chung S, Choi DE, Na KR, Shin YT, Sulikowska B, Johnson R, Grajewska M, Donderski R, Odrowaz-Sypniewska G, Manitius J, Pasquariello A, Innocenti M, Pasquariello G, Mattei P, Colombini E, Ricchiuti G, Sami N, Cupisti A, Rocchetti MT, Di Paolo S, Tamma G, Lasorsa D, Suriano IV, D'Apollo A, Papale M, Mastrofrancesco L, Grandaliano G, Svelto M, Valenti G, Gesualdo L, Wang C, Li Y, Jia N, Fan J, Vigotti FN, Daidola G, Colla L, Besso L, Segoloni GP, Rocchetti MT, Papale M, Di Paolo S, Vocino G, Suriano IV, D'Apollo A, Grandaliano G, Gesualdo L, Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L, Rivera F, Segarra A, Praga M, Vozmediano C, Rivera F, Lopez JM, Hernandez D, Pesickova S, Rysava R, Lenicek M, Potlukova E, Jancova E, Vitek L, Honsova E, Zavada J, Svarcova J, Kalousova M, Trendelenburg M, Tesar V, Li X, Ren H, Zhang W, Pan X, Zhang Q, Chen X, Xu Y, Shen P, Chen N, Hruskova Z, Mareckova H, Svobodova B, Jancova E, Bednarova V, Rysava R, Tesar V, Bobrova L, Kozlovskaya N, Khafizova E, Meteleva N, Shakhnova E, Alsuwaida A, Hussain S, Alghonaim M, AlOudah N, Ullah A, Kfoury H, Lorusso P, Bottai A, Cipollini I, Giorgetti M, Barsotti G, Goplani K, Kaswan K, Gera D, Patel H, Gumber M, Shah P, Vanikar A, Trivedi H, Gluhovschi C, Gluhovschi G, Potencz E, Lazar E, Trandafirescu V, Petrica L, Velciov S, Bozdog G, Bob F, Gadalean F, Vernic C, Cioca D, Bantis C, Heering P, Stangou M, Kouri NM, Schwandt C, Memmos D, Rump LC, Ivens K, Tofik R, Rippe B, Torffvit O, Bakoush O, Silska M, Lipkowska K, Warzywoda A, Soltysiak J, Blumczynski A, Musielak A, Ostalska-Nowicka D, Zachwieja J, Spartalis M, Stangou M, Pliakos K, Oikonomidou D, Pantzaki A, Rizopoulou E, Efstratiadis G, Memmos D, Okino VT, Moyses Neto M, Silva GEB, Vieira Neto O, Romao EA, Coelho EB, Dantas M, Liakou H, Stangou M, Ekonomidou D, Pantzaki A, Patinakis P, Sigounas V, Efstratiadis G, Memmos D, Shvetsov M, Bobkova I, Zheng A, Li O, Chebotareva N, Kamyshova E, Rudenko T, Gelpi R, Navarro I, Ngango L, Poveda R, Goma M, Torras J, Grinyo JM, Fulladosa X, Wang Y, Ivany J, Jardine M, Zhong F, Wang W, Ren H, Xie Y, Huang Q, Chen N, Chiappini MG, Di Girolamo M, Grosso A, Muzi L, Panetta V, Khafizova E, Kozlovskaya N, Bobrova L, Bobkova I, Avdonin P, Gluhovschi C, Gluhovschi G, Potencz E, Lazar E, Trandafirescu V, Petrica L, Velciov S, Bozdog G, Bob F, Gadalean F, Vernic C, Cioca D, Ito M, Kimachi M, Nishio S, Koike T, Choi H, Cho AJ, Jang HR, Lee JE, Huh W, Kim DJ, Oh HY, Kim YG. Clinical Nephrology: primary and secondary glomerulonephritis. Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.35] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Arnold R, Pianta T, Lin CY, Pussell B, Grinius V, Kiernan M, Jardine M, Krishnan A. P4.17 Novel neurophysiological insights into uraemic neuropathy: implications for clinical trials. Clin Neurophysiol 2011. [DOI: 10.1016/s1388-2457(11)60256-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
19
|
Vidotto AA, Jardine M, Helling C. Prospects for detection of exoplanet magnetic fields through bow-shock observations during transits. ACTA ACUST UNITED AC 2010. [DOI: 10.1111/j.1745-3933.2010.00991.x] [Citation(s) in RCA: 83] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
20
|
Ninomiya T, Perkovic V, Gallagher M, Jardine M, Cass A, Arima H, Anderson C, Neal B, Woodward M, Omae T, MacMahon S, Chalmers J. Lower blood pressure and risk of recurrent stroke in patients with chronic kidney disease: PROGRESS trial. Kidney Int 2008; 73:963-70. [DOI: 10.1038/ki.2008.5] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|
21
|
Abstract
Acute renal impairment secondary to interstitial nephritis is a rare complication of omeprazole. We describe a 50-year-old woman who took 20 mg omeprazole twice daily for endoscopically proved ulcerative esophagitis. At the same time, Duke's C colonic cancer was diagnosed and completely resected. Five fluorouracil/folinic acid adjuvant chemotherapy was tolerated without diarrhea or mouth ulceration. Renal function was normal before her first monthly cycle but markedly deteriorated immediately before the second cycle was due. The patient was symptomatic with lethargy, nausea, and mild vomiting, but she was clinically normotensive and only mildly dehydrated. Her serum creatinine concentration increased despite prolonged intravenous hydration, peaking at 4.4 mg/dl 1 week later. Results of a renal ultrasound were normal, and urinary microscopic findings were unremarkable. Renal biopsy showed interstitial nephritis, and renal function improved on cessation of omeprazole, eventually returning to normal. We describe the 12 cases of omeprazole-induced interstitial nephritis reported previously.
Collapse
Affiliation(s)
- D Yip
- Department of Medical Oncology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
| | | | | | | | | |
Collapse
|